Table 4.
Impact of radiation dose on the response of mLNs in SUVmax (A) and MTV (B) groups
| Group | Response | Mean dose±SD (Gy) | P-value | CR rate |
|---|---|---|---|---|
|
A
| ||||
| G1 | CR | 60.96±1.96 | 0.543 | 48.57 |
| Non-CR | 59.93±4.50 | |||
| G2 | CR | 58.89±4.16 | 0.556 | 59.46 |
| Non-CR | 58.28±2.38 | |||
| G3 | CR | 59.68±3.23 | 0.031 | 54.29 |
| Non-CR | 57.13±3.25 | |||
| G4 | CR | 61.98±2.51 | <0.001 | 30.56 |
| Non-CR | 56.99±3.94 | |||
|
| ||||
|
B
| ||||
| G1 | CR | 60.55±2.92 | 0.389 | 48.57 |
| Non-CR | 59.48±4.46 | |||
| G2 | CR | 59.07±4.34 | 0.500 | 59.46 |
| Non-CR | 58.59±4.46 | |||
| G3 | CR | 60.05±3.38 | 0.029 | 54.29 |
| Non-CR | 59.78±2.68 | |||
| G4 | CR | 61.15±2.08 | 0.001 | 30.56 |
| Non-CR | 56.94±3.71 | |||
Abbreviations: mLNs, metastatic lymph nodes; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; CR, complete response; non-CR, non-complete response; G, group.